Alto Neuroscience

Imagine a patient with major depression who has tried three different antidepressants without success. Instead of guessing which medication to try next, their psychiatrist attaches a single EEG electr

The mid-stage misfire of Alto Neuroscience’s depression candidate ALTO-100 is not just bad – and predictable given that the asset had already failed in the disease – it also calls into question the co

FDA Advising CMS On RWE Studies Amid IRA Price Negotiations The US Food and Drug Administration is advising the Centers for Medicare and Medicaid Services on the types of real-world evidence research

FDA Advising CMS On RWE Studies Amid IRA Price Negotiations The US Food and Drug Administration is advising the Centers for Medicare and Medicaid Services on the types of real-world evidence research